财务调查：Plus Therapeutics（纳斯达克股票代码：PSTV）Vs.阿波罗内外科（纳斯达克股票代码：APEN）

Plus Therapeutics (NASDAQ:PSTV – Get Rating) and Apollo Endosurgery (NASDAQ:APEN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Plus Therapeutics and Apollo Endosurgery's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Plus Therapeutics and Apollo Endosurgery, as provided by MarketBeat.com.

Plus Therapeutics presently has a consensus price target of $3.88, indicating a potential upside of 1,335.19%. Apollo Endosurgery has a consensus price target of $10.00, indicating a potential upside of ∞. Given Apollo Endosurgery's higher probable upside, analysts plainly believe Apollo Endosurgery is more favorable than Plus Therapeutics.

Insider and Institutional Ownership

10.5% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 76.0% of Apollo Endosurgery shares are owned by institutional investors. 2.3% of Plus Therapeutics shares are owned by company insiders. Comparatively, 17.3% of Apollo Endosurgery shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Plus Therapeutics and Apollo Endosurgery's top-line revenue, earnings per share and valuation.

Plus Therapeutics has higher earnings, but lower revenue than Apollo Endosurgery. Plus Therapeutics is trading at a lower price-to-earnings ratio than Apollo Endosurgery, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Plus Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Apollo Endosurgery has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500.

Summary

Apollo Endosurgery beats Plus Therapeutics on 7 of the 13 factors compared between the two stocks.

About Plus Therapeutics

(Get Rating)

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

About Apollo Endosurgery

(Get Rating)

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.